MedTrace Logo

Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat

NCT02920190 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-09-21

No results posted yet for this study

Summary

The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on the fat of the heart and some fat cells in blood.

Conditions

Interventions

DRUG

Liraglutide

1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • James Hoffman, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-09-01
Completion
2021-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02920190 on ClinicalTrials.gov